At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
MM36 topical ointment, 1%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
In Brief
A Phase 2 clinical trial evaluating MM36 topical ointment, 1% for Atopic Dermatitis. Completed, enrolled 32 participants across 12 sites in 3 countries.
Detailed Summary
The purpose of this study is to assess the pharmacokinetic parameters and safety of topical MM36 (OPA-15406) ointment in pediatric subjects with atopic dermatitis under maximal use conditions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesHonduras, Panama, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartOct 2016
First PostedOct 2016
Primary CompletionJun 2017
TodayJul 2026
First PostedOct 26, 2016
Enrollment StartOct 1, 2016
Primary CompletionJun 8, 2017
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 9.7 years ago
Interventions
MM36 topical ointment, 1%drug
Twice daily application for 28 consecutive days